The Nebula Antibody Platform
The Nebula Antibody Platform is a proprietary end-to-end antibody discovery system. It has been carefully-designed to deliver highly functional preclinical-ready candidates against difficult targets for a range of therapeutic and diagnostic applications.
About Immune Biosolutions
We are an innovative biotechnology company specializing in the discovery and engineering of humanized chicken antibodies for targets with recognized, therapeutic and diagnostic potential.
Using our unique Nebula Antibody Platform, we are developing a robust internal portfolio of highly effective preclinical-ready antibodies. Our initial areas of interest are oncology and gastrointestinal health.
Latest newsSee all >
Chief executive officer, Frédéric Leduc, will be representing Immune Biosolutions this week at...
After winning a pitch competition earlier this year, Immune Biosolutions' founders are...
Scientific advisory board
University of North Carolina
University of Toronto
Université de Montréal